The aim of our study was to evaluate the efficacy of CDK4/6i plus a change in endocrine therapy, after progression on initial CDK4/6i + endocrine therapy in patients of ER+ HER2- advanced breast cancer and to identify patient characteristics associated with differential benefits. Here, CDK4 is linked to breast carcinoma.